Acquisitions, licensing and partnerships across pharma and biotech.
The US biotech says non-dilutive deals, including a manufacturing sale and a ZYNYZ royalty sale, extend its funding as it focuses on investigational ADC MGC026.
The US biotech posted about $0.7m in royalty revenue and $5.8m in cash, and plans a Q1 2027 close for its Santersus acquisition.
The cell therapy developer reported that laromestrocel missed its primary endpoint in infants with hypoplastic left heart syndrome, and is now weighing a sale or merger.
The RNAi company reported a $12.4M third-quarter loss and $247.7M in cash, alongside positive Phase 2 divesiran data in polycythemia vera and a pending acquisition by Merck KGaA.
The US biotech reported third-quarter results alongside the divestment, and said VIRAGE2 enrolment in metastatic pancreatic cancer should finish in the fourth quarter of 2026.
The US ophthalmology developer has acquired rights outside Asia to mitucapistat and has asked the FDA for a pre-IND meeting and orphan drug designation.
The competition authority found problems only in UK vehicle refinish coatings supply, and the companies plan to offer the divestment already agreed with the European Commission.
Lilly gains exclusive rights to develop estetrol combinations in women's health and cardiometabolic disease, plus a US co-commercialisation option on Richter's FYLREVY, and will buy about $15M of Richter shares.
The eye-care company reported nine-month sales of $8.2bn, with dry eye products and surgical equipment launches driving growth, and highlighted its planned purchase of Neurotech Pharmaceuticals.
Eocene's subsidiary has granted Hospital Line SA exclusive rights to market the CE-marked CG-100 intraluminal bypass device in two Mediterranean markets.
The deal brings ZYNRELEF, APONVIE, CINVANTI and SUSTOL under CorMedix, with about $150 million in trailing-12-month net revenue and a Pharmakon term loan backing the purchase.
Ocugen has granted Sydney-based Celairis exclusive regional rights to its investigational modifier gene therapy, with Phase 3 top-line data expected in the first quarter of 2027.
The alpha-emitting radiopharmaceutical developer also reported EU orphan status for bamzireotide navoxetan, about $202 million in cash and a Q3 net loss of $32.4 million.
CorMedix will acquire substantially all of Heron's assets, including ZYNRELEF, APONVIE, CINVANTI and SUSTOL, for cash, shares and contingent earn-outs, with closing expected in Q1 2027.
CorMedix has agreed to buy substantially all of Heron's assets, including four hospital-use products for postoperative pain and nausea and vomiting, with closing expected in the first quarter of 2027.
The CRO has signed definitive agreements for the Pennsylvania units, with up to $75m in further performance-based payments, through a consortium structure that first takes Frontage private.
Edesa Biotech grants Kyorin Pharmaceutical exclusive Japanese rights to its anti-TLR4 antibody for acute respiratory distress syndrome, with $12m upfront and further milestones and royalties.
The US oncology-focused biotech has bought a Phase 2-ready selective JAK1 inhibitor and a preclinical PKCθ programme for undisclosed cash, with no future royalties or milestones owed to Aqilion.
The SPAC and Brains Bioceutical signed a definitive agreement on 5 November 2026, implying a pre-money equity value of about $750 million, with completion subject to closing conditions.
ANI Pharmaceuticals announced a proposed offer for Egetis Therapeutics alongside its third-quarter results, aiming to add EMCITATE to its rare disease portfolio; the deal has not closed.